Stock Analysis

India Pesticides Full Year 2024 Earnings: Misses Expectations

NSEI:IPL
Source: Shutterstock

India Pesticides (NSE:IPL) Full Year 2024 Results

Key Financial Results

  • Revenue: ₹6.80b (down 23% from FY 2023).
  • Net income: ₹601.7m (down 58% from FY 2023).
  • Profit margin: 8.8% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue.
  • EPS: ₹5.23 (down from ₹12.44 in FY 2023).
revenue-and-expenses-breakdown
NSEI:IPL Revenue and Expenses Breakdown August 2nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

India Pesticides Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 27%. Earnings per share (EPS) also missed analyst estimates by 51%.

In the last 12 months, the only revenue segment was Agro Chemicals contributing ₹6.80b. Notably, cost of sales worth ₹4.05b amounted to 60% of total revenue thereby underscoring the impact on earnings.Explore how IPL's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.

Performance of the Indian Chemicals industry.

The company's shares are up 3.1% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for India Pesticides that you should be aware of.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.